Dimensional Fund Advisors LP Decreases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Dimensional Fund Advisors LP lessened its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 67.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 31,608 shares of the biotechnology company’s stock after selling 64,364 shares during the period. Dimensional Fund Advisors LP owned approximately 0.10% of AnaptysBio worth $418,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock valued at $24,411,000 after buying an additional 143,584 shares during the period. Geode Capital Management LLC raised its holdings in AnaptysBio by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company’s stock valued at $6,444,000 after buying an additional 21,196 shares during the period. Victory Capital Management Inc. raised its holdings in AnaptysBio by 41.0% during the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock valued at $4,428,000 after buying an additional 97,200 shares during the period. Jennison Associates LLC increased its stake in AnaptysBio by 1.6% in the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock worth $3,563,000 after purchasing an additional 4,242 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in AnaptysBio by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company’s stock worth $2,199,000 after purchasing an additional 5,733 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ANAB shares. Wells Fargo & Company increased their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Guggenheim increased their target price on AnaptysBio from $52.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and issued a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on AnaptysBio in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus target price of $35.88.

AnaptysBio Trading Down 0.9%

Shares of AnaptysBio stock opened at $20.22 on Friday. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31. The stock’s fifty day moving average price is $18.97 and its 200-day moving average price is $18.29. The firm has a market cap of $594.06 million, a P/E ratio of -3.33 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. Analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has authorized a share repurchase plan on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.